ProposalWorkspaceFederal OpportunitiesDepartment of Defense

HT9426-27-NOI-049825

Active HT9426-27-NOI-049825 Special NoticeDefense Health Agency (DHA)
The full text, documents and contacts of this bid come with a ProposalWorkspace plan.Get started

At a glance

Defense Health Agency of Defense Health Agency (DHA) posted this Special Notice on Nov 18, 2026. Responses are due Dec 31, 2026. NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)), product or service code AN14 (Health R&D Services; Health Care Services; R&D Administrative Expenses). Place of performance: Pennsylvania 19422. Solicitation number HT9426-27-NOI-049825.

Solicitation details

General information

Solicitation number
HT9426-27-NOI-049825
Notice type
Special Notice
Place of performance
Pennsylvania 19422

Classification

NAICS
541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Product or service
AN14Health R&D Services; Health Care Services; R&D Administrative Expenses

Agency

Department
Department of Defense
Sub-tier
Defense Health Agency (DHA)
Office
Defense Health Agency

Description

From SAM.gov
The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574. The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice. THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.. Responsible, interested parties may identify their interest by submitting capability statements (using PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firms ability to provide the stated capability. Information and materials submitted in response to this request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.

Documents

1 file

Subscribe to download this file.

  • Notice of Intent to Sole Source - M201 ProDrug_Approved for posting 16NOV26.pdf
    126 KB
    Download

Similar open bids

Same NAICS 541715

More from Defense Health Agency (DHA)

Open bids, other NAICS codes